{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,17]],"date-time":"2026-09-17T00:46:05Z","timestamp":1789605965472,"version":"build-2803163510"},"reference-count":62,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2009,8,1]],"date-time":"2009-08-01T00:00:00Z","timestamp":1249084800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2009,8,1]],"date-time":"2009-08-01T00:00:00Z","timestamp":1249084800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Seminars in Oncology"],"published-print":{"date-parts":[[2009,8]]},"DOI":"10.1053\/j.seminoncol.2009.06.007","type":"journal-article","created":{"date-parts":[[2009,8,6]],"date-time":"2009-08-06T04:43:09Z","timestamp":1249533789000},"page":"324-337","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":30,"title":["Sarcomas With Spindle Cell Morphology"],"prefix":"10.1053","volume":"36","author":[{"given":"Paola","family":"Collini","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Poul H.B.","family":"Sorensen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shreyaskumar","family":"Patel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jean-Yves","family":"Blay","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rolf D.","family":"Issels","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert G.","family":"Maki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mikael","family":"Eriksson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xavier Garcia","family":"del Muro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1053\/j.seminoncol.2009.06.007_bib1","series-title":"Pathology and genetics of tumours of soft tissue and bone","author":"Fletcher","year":"2002"},{"key":"10.1053\/j.seminoncol.2009.06.007_bib2","series-title":"Atlas of tumor pathology: tumors of soft tissue","author":"Kempson","year":"2001"},{"key":"10.1053\/j.seminoncol.2009.06.007_bib3","series-title":"Soft tissue tumors","author":"Weiss","year":"2008"},{"key":"10.1053\/j.seminoncol.2009.06.007_bib4","doi-asserted-by":"crossref","first-page":"866","DOI":"10.1200\/JCO.2005.07.088","article-title":"Molecular and clinical analysis of locally advanced dermatofibrosarcoma protuberans treated with imatinib: Imatinib Target Exploration Consortium Study B2225","volume":"23","author":"McArthur","year":"2005","journal-title":"J Clin Oncol"},{"key":"10.1053\/j.seminoncol.2009.06.007_bib5","doi-asserted-by":"crossref","first-page":"623","DOI":"10.1002\/ijc.10535","article-title":"Differential sensitivity to imatinib of 2 patients with metastatic sarcoma arising from dermatofibrosarcoma protuberans","volume":"100","author":"Maki","year":"2002","journal-title":"Int J Cancer"},{"key":"10.1053\/j.seminoncol.2009.06.007_bib6","doi-asserted-by":"crossref","first-page":"3586","DOI":"10.1200\/JCO.2002.01.027","article-title":"Molecular targeting of platelet-derived growth factor B by imatinib mesylate in a patient with metastatic dermatofibrosarcoma protuberans","volume":"20","author":"Rubin","year":"2002","journal-title":"J Clin Oncol"},{"key":"10.1053\/j.seminoncol.2009.06.007_bib7","doi-asserted-by":"crossref","first-page":"412","DOI":"10.1097\/00001622-200207000-00008","article-title":"Chromosomal translocations and sarcomas","volume":"14","author":"Bennicelli","year":"2002","journal-title":"Curr Opin Oncol"},{"key":"10.1053\/j.seminoncol.2009.06.007_bib8","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1016\/S1383-5742(00)00006-5","article-title":"Recurrent chromosome aberrations in cancer","volume":"462","author":"Mitelman","year":"2000","journal-title":"Mutat Res"},{"key":"10.1053\/j.seminoncol.2009.06.007_bib9","doi-asserted-by":"crossref","first-page":"532","DOI":"10.1053\/hp.2000.6706","article-title":"Contribution of molecular genetic data to the classification of sarcomas","volume":"31","author":"Ladanyi","year":"2000","journal-title":"Hum Pathol"},{"key":"10.1053\/j.seminoncol.2009.06.007_bib10","doi-asserted-by":"crossref","first-page":"1248","DOI":"10.1200\/JCO.1998.16.4.1248","article-title":"EWS-FLI1 fusion transcript structure is an independent determinant of prognosis in Ewing's sarcoma","volume":"16","author":"de Alava","year":"1998","journal-title":"J Clin Oncol"},{"key":"10.1053\/j.seminoncol.2009.06.007_bib11","first-page":"135","article-title":"Impact of SYT-SSX fusion type on the clinical behavior of synovial sarcoma: a multi-institutional retrospective study of 243 patients","volume":"62","author":"Ladanyi","year":"2002","journal-title":"Cancer Res"},{"key":"10.1053\/j.seminoncol.2009.06.007_bib12","doi-asserted-by":"crossref","first-page":"2672","DOI":"10.1200\/JCO.2002.03.137","article-title":"PAX3-FKHR and PAX7-FKHR gene fusions are prognostic indicators in alveolar rhabdomyosarcoma: a report from the Children's Oncology Group","volume":"20","author":"Sorensen","year":"2002","journal-title":"J Clin Oncol"},{"key":"10.1053\/j.seminoncol.2009.06.007_bib13","doi-asserted-by":"crossref","first-page":"1245","DOI":"10.1200\/JCO.1996.14.4.1245","article-title":"Does expression of different EWS chimeric transcripts define clinically distinct risk groups of Ewing tumor patients?","volume":"14","author":"Zoubek","year":"1996","journal-title":"J Clin Oncol"},{"key":"10.1053\/j.seminoncol.2009.06.007_bib14","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1038\/475","article-title":"Translocations, cancer and the puzzle of specificity","volume":"19","author":"Barr","year":"1998","journal-title":"Nat Genet"},{"key":"10.1053\/j.seminoncol.2009.06.007_bib15","doi-asserted-by":"crossref","first-page":"1325","DOI":"10.1016\/S0046-8177(97)90213-6","article-title":"Radiation-associated synovial sarcoma","volume":"28","author":"van de Rijn","year":"1997","journal-title":"Hum Pathol"},{"key":"10.1053\/j.seminoncol.2009.06.007_bib16","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1080\/13577140220127530","article-title":"Molecular approaches to sarcoma therapy","volume":"6","author":"Olsen","year":"2002","journal-title":"Sarcoma"},{"key":"10.1053\/j.seminoncol.2009.06.007_bib17","doi-asserted-by":"crossref","first-page":"5763","DOI":"10.1038\/sj.onc.1204597","article-title":"Chromosomal translocation master genes, mouse models and experimental therapeutics","volume":"20","author":"Rabbitts","year":"2001","journal-title":"Oncogene"},{"key":"10.1053\/j.seminoncol.2009.06.007_bib18","doi-asserted-by":"crossref","first-page":"554","DOI":"10.1016\/S1471-4914(01)02244-4","article-title":"Chromosomal translocations in sarcomas: prospects for therapy","volume":"7","author":"Tomescu","year":"2001","journal-title":"Trends Mol Med"},{"key":"10.1053\/j.seminoncol.2009.06.007_bib19","first-page":"1941","article-title":"Soft tissue sarcomas of adults: state of the translational science","volume":"9","author":"Borden","year":"2003","journal-title":"Clin Cancer Res"},{"key":"10.1053\/j.seminoncol.2009.06.007_bib20","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1056\/NEJM199801153380303","article-title":"SYT-SSX gene fusion as a determinant of morphology and prognosis in synovial sarcoma","volume":"338","author":"Kawai","year":"1998","journal-title":"N Engl J Med"},{"key":"10.1053\/j.seminoncol.2009.06.007_bib21","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1038\/ng0693-175","article-title":"Fusion of the dominant negative transcription regulator CHOP with a novel gene FUS by translocation t(12;16) in malignant liposarcoma","volume":"4","author":"Rabbitts","year":"1993","journal-title":"Nat Genet"},{"key":"10.1053\/j.seminoncol.2009.06.007_bib22","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1038\/ng0298-184","article-title":"A novel ETV6-NTRK3 gene fusion in congenital fibrosarcoma","volume":"18","author":"Knezevich","year":"1998","journal-title":"Nat Genet"},{"key":"10.1053\/j.seminoncol.2009.06.007_bib23","first-page":"5046","article-title":"ETV6-NTRK3 gene fusions and trisomy 11 establish a histogenetic link between mesoblastic nephroma and congenital fibrosarcoma","volume":"58","author":"Knezevich","year":"1998","journal-title":"Cancer Res"},{"key":"10.1053\/j.seminoncol.2009.06.007_bib24","doi-asserted-by":"crossref","first-page":"5684","DOI":"10.1038\/sj.onc.1205669","article-title":"ETV6-NTRK3 transformation requires insulin-like growth factor 1 receptor signaling and is associated with constitutive IRS-1 tyrosine phosphorylation","volume":"21","author":"Morrison","year":"2002","journal-title":"Oncogene"},{"key":"10.1053\/j.seminoncol.2009.06.007_bib25","doi-asserted-by":"crossref","first-page":"1754","DOI":"10.1128\/MCB.26.5.1754-1769.2006","article-title":"The insulin-like growth factor I receptor is required for Akt activation and suppression of anoikis in cells transformed by the ETV6-NTRK3 chimeric tyrosine kinase","volume":"26","author":"Martin","year":"2006","journal-title":"Mol Cell Biol"},{"key":"10.1053\/j.seminoncol.2009.06.007_bib26","first-page":"35064","article-title":"Combination therapy with temozolomide and bevacizumab in the treatment of hemangiopericytoma\/solitary fibrous tumor: an updated analysis [abstract]","volume":"14","author":"Park","year":"2008","journal-title":"Proc Connective Tissue Oncol Soc"},{"key":"10.1053\/j.seminoncol.2009.06.007_bib27","doi-asserted-by":"crossref","first-page":"840","DOI":"10.1200\/JCO.1987.5.6.840","article-title":"Randomized comparison of three adriamycin regimens for metastatic soft tissue sarcomas","volume":"5","author":"Borden","year":"1987","journal-title":"J Clin Oncol"},{"key":"10.1053\/j.seminoncol.2009.06.007_bib28","doi-asserted-by":"crossref","first-page":"2755","DOI":"10.1200\/JCO.2006.10.4117","article-title":"Randomized phase II study of gemcitabine and docetaxel compared with gemcitabine alone in patients with metastatic soft tissue sarcomas: results of Sarcoma Alliance for Research Through Collaboration study 002","volume":"25","author":"Maki","year":"2007","journal-title":"J Clin Oncol"},{"key":"10.1053\/j.seminoncol.2009.06.007_bib29","doi-asserted-by":"crossref","first-page":"5269","DOI":"10.1200\/JCO.2008.17.3146","article-title":"Phase II trial of weekly paclitaxel for unresectable angiosarcoma: the ANGIOTAX study","volume":"26","author":"Penel","year":"2008","journal-title":"J Clin Oncol"},{"key":"10.1053\/j.seminoncol.2009.06.007_bib30","doi-asserted-by":"crossref","first-page":"2506","DOI":"10.1002\/1097-0142(19940515)73:10<2506::AID-CNCR2820731009>3.0.CO;2-S","article-title":"Synovial sarcoma","volume":"73","author":"Rosen","year":"1994","journal-title":"Cancer"},{"key":"10.1053\/j.seminoncol.2009.06.007_bib31","doi-asserted-by":"crossref","first-page":"5484","DOI":"10.1200\/JCO.2005.05.028","article-title":"Ecteinascidin-743 (ET-743) for chemotherapy-naive patients with advanced soft tissue sarcomas: multicenter phase II and pharmacokinetic study","volume":"23","author":"Garcia-Carbonero","year":"2005","journal-title":"J Clin Oncol"},{"key":"10.1053\/j.seminoncol.2009.06.007_bib32","doi-asserted-by":"crossref","first-page":"1480","DOI":"10.1200\/JCO.2004.02.098","article-title":"Phase II and pharmacokinetic study of ecteinascidin 743 in patients with progressive sarcomas of soft tissues refractory to chemotherapy","volume":"22","author":"Garcia-Carbonero","year":"2004","journal-title":"J Clin Oncol"},{"key":"10.1053\/j.seminoncol.2009.06.007_bib33","doi-asserted-by":"crossref","first-page":"595","DOI":"10.1016\/S1470-2045(07)70175-4","article-title":"Efficacy of trabectedin (ecteinascidin-743) in advanced pretreated myxoid liposarcomas: a retrospective study","volume":"8","author":"Grosso","year":"2007","journal-title":"Lancet Oncol"},{"key":"10.1053\/j.seminoncol.2009.06.007_bib34","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1007\/s12032-008-9085-8","article-title":"Efficacy of topotecan plus vincristine and doxorubicin in children with recurrent\/refractory rhabdomyosarcoma","volume":"26","author":"Meazza","year":"2009","journal-title":"Med Oncol"},{"key":"10.1053\/j.seminoncol.2009.06.007_bib35","doi-asserted-by":"crossref","first-page":"612","DOI":"10.1002\/cncr.11937","article-title":"High-dose tamoxifen and sulindac as first-line treatment for desmoid tumors","volume":"100","author":"Hansmann","year":"2004","journal-title":"Cancer"},{"key":"10.1053\/j.seminoncol.2009.06.007_bib36","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1016\/j.critrevonc.2007.06.011","article-title":"The management of patients with uterine sarcoma: a debated clinical challenge","volume":"65","author":"Gadducci","year":"2008","journal-title":"Crit Rev Oncol Hematol"},{"key":"10.1053\/j.seminoncol.2009.06.007_bib37","doi-asserted-by":"crossref","first-page":"1195","DOI":"10.1200\/JCO.2005.04.0717","article-title":"Clinical and molecular studies of the effect of imatinib on advanced aggressive fibromatosis (desmoid tumor)","volume":"24","author":"Heinrich","year":"2006","journal-title":"J Clin Oncol"},{"key":"10.1053\/j.seminoncol.2009.06.007_bib38","doi-asserted-by":"crossref","first-page":"7135","DOI":"10.1200\/JCO.2005.16.139","article-title":"Phase II study of doxorubicin and bevacizumab for patients with metastatic soft-tissue sarcomas","volume":"23","author":"D'Adamo","year":"2005","journal-title":"J Clin Oncol"},{"key":"10.1053\/j.seminoncol.2009.06.007_bib39","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1016\/S1470-2045(07)70169-9","article-title":"Opportunities for improving the therapeutic ratio for patients with sarcoma","volume":"8","author":"Wunder","year":"2007","journal-title":"Lancet Oncol"},{"key":"10.1053\/j.seminoncol.2009.06.007_bib40","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1200\/JCO.2007.12.0345","article-title":"Phase I trial of the novel mammalian target of rapamycin inhibitor deforolimus (AP23573; MK-8669) administered intravenously daily for 5 days every 2 weeks to patients with advanced malignancies","volume":"26","author":"Mita","year":"2008","journal-title":"J Clin Oncol"},{"key":"10.1053\/j.seminoncol.2009.06.007_bib41","doi-asserted-by":"crossref","first-page":"1647","DOI":"10.1016\/S0140-6736(97)08165-8","article-title":"Adjuvant chemotherapy for localised resectable soft-tissue sarcoma of adults: meta-analysis of individual data","volume":"350","year":"1997","journal-title":"Lancet"},{"key":"10.1053\/j.seminoncol.2009.06.007_bib42","doi-asserted-by":"crossref","first-page":"1238","DOI":"10.1200\/JCO.2001.19.5.1238","article-title":"Adjuvant chemotherapy for adult soft tissue sarcomas of the extremities and girdles: results of the Italian randomized cooperative trial","volume":"19","author":"Frustaci","year":"2001","journal-title":"J Clin Oncol"},{"issue":"Suppl 2","key":"10.1053\/j.seminoncol.2009.06.007_bib43","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1159\/000073366","article-title":"Ifosfamide in the adjuvant therapy of soft tissue sarcomas","volume":"65","author":"Frustaci","year":"2003","journal-title":"Oncology"},{"key":"10.1053\/j.seminoncol.2009.06.007_bib44","doi-asserted-by":"crossref","first-page":"10008","DOI":"10.1200\/jco.2007.25.18_suppl.10008","article-title":"Adjuvant chemotherapy with doxorubicin and ifosfamide in resected soft tissue sarcoma: interim analysis of a randomised phase III trial [abstract]","volume":"25","author":"Woll","year":"2007","journal-title":"J Clin Oncol"},{"key":"10.1053\/j.seminoncol.2009.06.007_bib45","doi-asserted-by":"crossref","first-page":"573","DOI":"10.1002\/cncr.23592","article-title":"A systematic meta-analysis of randomized controlled trials of adjuvant chemotherapy for localized resectable soft-tissue sarcoma","volume":"113","author":"Pervaiz","year":"2008","journal-title":"Cancer"},{"key":"10.1053\/j.seminoncol.2009.06.007_bib46","doi-asserted-by":"crossref","first-page":"811","DOI":"10.1016\/0014-2964(79)90158-0","article-title":"Evaluation of adjuvant therapy in soft tissue sarcoma","volume":"15","author":"Pinedo","year":"1979","journal-title":"Eur J Cancer"},{"key":"10.1053\/j.seminoncol.2009.06.007_bib47","doi-asserted-by":"crossref","first-page":"10525","DOI":"10.1200\/jco.2008.26.15_suppl.10525","article-title":"The end of adjuvant chemotherapy era with doxorubicin-based regimen in resected high-grade soft tissue sarcoma: pooled analysis of the two STBSG-EORTC phase III clinical trials [abstract]","volume":"26","author":"Le Cesne","year":"2008","journal-title":"J Clin Oncol"},{"key":"10.1053\/j.seminoncol.2009.06.007_bib48","doi-asserted-by":"crossref","first-page":"9522","DOI":"10.1200\/jco.2006.24.18_suppl.9522","article-title":"DNA repair functionality modulates the clinical outcome of patients with advanced sarcoma treated with trabectedin (ET-743) [abstract]","volume":"24","author":"Sch\u00f6ffski","year":"2006","journal-title":"J Clin Oncol"},{"key":"10.1053\/j.seminoncol.2009.06.007_bib49","doi-asserted-by":"crossref","first-page":"1096","DOI":"10.1016\/S0959-8049(01)00083-1","article-title":"A randomised phase II study on neo-adjuvant chemotherapy for \u2018high-risk\u2019 adult soft-tissue sarcoma","volume":"37","author":"Gortzak","year":"2001","journal-title":"Eur J Cancer"},{"key":"10.1053\/j.seminoncol.2009.06.007_bib50","doi-asserted-by":"crossref","first-page":"3144","DOI":"10.1200\/JCO.2006.09.7717","article-title":"Phase III trial of two investigational schedules of ifosfamide compared with standard-dose doxorubicin in advanced or metastatic soft tissue sarcoma: a European Organisation for Research and Treatment of Cancer Soft Tissue and Bone Sarcoma Group study","volume":"25","author":"Lorigan","year":"2007","journal-title":"J Clin Oncol"},{"key":"10.1053\/j.seminoncol.2009.06.007_bib51","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1016\/S1470-2045(02)00818-5","article-title":"Hyperthermia in combined treatment of cancer","volume":"3","author":"Wust","year":"2002","journal-title":"Lancet Oncol"},{"key":"10.1053\/j.seminoncol.2009.06.007_bib52","doi-asserted-by":"crossref","first-page":"312","DOI":"10.1007\/s00262-005-0052-3","article-title":"Effects of thermal stress on tumor antigenicity and recognition by immune effector cells","volume":"55","author":"Milani","year":"2006","journal-title":"Cancer Immunol Immunother"},{"key":"10.1053\/j.seminoncol.2009.06.007_bib53","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1080\/02656730600661149","article-title":"Thermal monitoring: Invasive, minimal-invasive and non-invasive approaches","volume":"22","author":"Wust","year":"2006","journal-title":"Int J Hyperthermia"},{"key":"10.1053\/j.seminoncol.2009.06.007_bib54","doi-asserted-by":"crossref","first-page":"1373","DOI":"10.1002\/cncr.22114","article-title":"Noninvasive magnetic resonance thermography of soft tissue sarcomas during regional hyperthermia: correlation with response and direct thermometry","volume":"107","author":"Gellermann","year":"2006","journal-title":"Cancer"},{"issue":"Suppl 2","key":"10.1053\/j.seminoncol.2009.06.007_bib55","first-page":"S233","article-title":"Preoperative systemic etoposide\/ifosfamide\/doxorubicin chemotherapy combined with regional hyperthermia in high-risk sarcoma: a pilot study","volume":"31","author":"Issels","year":"1993","journal-title":"Cancer Chemother Pharmacol"},{"key":"10.1053\/j.seminoncol.2009.06.007_bib56","doi-asserted-by":"crossref","DOI":"10.1016\/S0959-8049(01)00183-6","article-title":"Neoadjuvant chemotherapy combined with regional hyperthermia (RHT) for locally advanced primary or recurrent high-risk adult soft-tissue sarcomas (STS) of adults: long-term results of a phase II study","volume":"37","author":"Issels","year":"2001","journal-title":"Eur J Cancer"},{"key":"10.1053\/j.seminoncol.2009.06.007_bib57","doi-asserted-by":"crossref","first-page":"3156","DOI":"10.1200\/JCO.2002.07.146","article-title":"Response to neoadjuvant chemotherapy combined with regional hyperthermia predicts long-term survival for adult patients with retroperitoneal and visceral high-risk soft tissue sarcomas","volume":"20","author":"Wendtner","year":"2002","journal-title":"J Clin Oncol"},{"key":"10.1053\/j.seminoncol.2009.06.007_bib58","doi-asserted-by":"crossref","first-page":"4341","DOI":"10.4049\/jimmunol.158.9.4341","article-title":"Heat shock protein 72 on tumor cells","volume":"158","author":"Multhoff","year":"1997","journal-title":"J Immunol"},{"key":"10.1053\/j.seminoncol.2009.06.007_bib59","doi-asserted-by":"crossref","first-page":"457","DOI":"10.3109\/02656739409009351","article-title":"Arrhenius relationships from the molecule and cell to the clinic","volume":"10","author":"Dewey","year":"1994","journal-title":"Int J Hyperthermia"},{"issue":"18S","key":"10.1053\/j.seminoncol.2009.06.007_bib60","doi-asserted-by":"crossref","first-page":"10009","DOI":"10.1200\/jco.2007.25.18_suppl.10009","volume":"25","author":"Issels","year":"2007","journal-title":"J Clin Oncol"},{"issue":"Suppl 4","key":"10.1053\/j.seminoncol.2009.06.007_bib61","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1016\/S1359-6349(07)71481-7","article-title":"Early progression in patients with high-risk soft tissue sarcomas (STS): a phase III randomized prospective trial (EORTC\/ESHO intergroup trial) of neoadjuvant chemotherapy with or without regional hyperthermia (RHT) [abstract 7504]","volume":"5","author":"Lindner","year":"2007","journal-title":"Eur J Cancer"},{"key":"10.1053\/j.seminoncol.2009.06.007_bib62","doi-asserted-by":"crossref","first-page":"438","DOI":"10.1097\/CCO.0b013e3283025e50","article-title":"Regional hyperthermia in high-risk soft tissue sarcomas","volume":"20","author":"Issels","year":"2008","journal-title":"Curr Opin Oncol"}],"container-title":["Seminars in Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0093775409001079?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0093775409001079?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,25]],"date-time":"2025-09-25T12:52:46Z","timestamp":1758804766000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0093775409001079"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2009,8]]},"references-count":62,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2009,8]]}},"alternative-id":["S0093775409001079"],"URL":"https:\/\/doi.org\/10.1053\/j.seminoncol.2009.06.007","relation":{},"ISSN":["0093-7754"],"issn-type":[{"value":"0093-7754","type":"print"}],"subject":[],"published":{"date-parts":[[2009,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Sarcomas With Spindle Cell Morphology","name":"articletitle","label":"Article Title"},{"value":"Seminars in Oncology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1053\/j.seminoncol.2009.06.007","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2009 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}